Molecular Stratification of Fragility Fracture Risk

Abstract

Fragility fractures present a significant clinical and socioeconomic challenge, particularly in aging populations. Recent advances in molecular biology have enhanced our understanding of fracture risk beyond traditional clinical and densitometric predictors. Molecular stratification leverages genetic, epigenetic, and biochemical markers to more accurately assess individual susceptibility to fragility fractures. This review synthesizes current evidence on molecular mechanisms underlying bone fragility, highlights risk factors and diagnostic approaches incorporating molecular stratification, discusses updated management strategies, and evaluates emerging therapies. Clinical integration of molecular profiling holds the promise of individualized risk assessment and targeted interventions, potentially transforming fracture prevention paradigms for at-risk populations.

Introduction

Fragility fractures, defined as fractures that result from low-energy trauma insufficient to cause injury in healthy bone, remain a leading cause of disability, reduced quality of life, and mortality in older adults. The increasing global prevalence of osteoporosis and related fractures underscores the need for improved stratification of fracture risk. Traditional risk assessment models, such as FRAX, incorporate clinical parameters and bone mineral density (BMD) but have limitations in sensitivity and specificity. Recent advances in molecular medicine offer novel tools for risk stratification, enabling identification of high-risk individuals who may otherwise be missed by conventional approaches. This article provides a comprehensive review of molecular stratification in fragility fracture risk, aiming to guide clinicians in utilizing emerging evidence to optimize patient care.

Epidemiology / Disease Burden

Globally, fragility fractures account for millions of hospitalizations annually, with an estimated 8.9 million osteoporotic fractures reported worldwide each year. Hip, vertebral, and wrist fractures are most common, with hip fractures contributing disproportionately to morbidity and mortality. The lifetime risk of a fragility fracture after age 50 is approximately 50% in women and 20% in men. The economic burden is substantial, with direct and indirect costs projected to rise due to population aging. Notably, many individuals who sustain fragility fractures do not meet the WHO criteria for osteoporosis based on BMD alone, highlighting the inadequacy of current risk stratification methods and the need for more nuanced molecular approaches.

Pathophysiology

Fragility fractures result from a mismatch between skeletal strength and mechanical load. While reduced bone mass is a key determinant, bone quality encompassing microarchitecture, turnover, mineralization, and accumulated microdamage plays a critical role. Molecular determinants of bone fragility include genetic polymorphisms, epigenetic modifications, and altered expression of bone matrix proteins, cytokines, and signaling molecules. Variations in genes such as COL1A1, LRP5, and SOST have been linked to differences in bone strength and fracture risk. Additionally, dysregulation of the Wnt/β-catenin pathway, RANK/RANKL/OPG axis, and oxidative stress contribute to compromised bone integrity. Molecular profiling thus provides insight into the underlying biological mechanisms predisposing individuals to fracture.

Risk Factors

Established risk factors for fragility fractures include advanced age, female sex, prior fracture, low body mass index, glucocorticoid use, smoking, excessive alcohol consumption, and comorbidities such as rheumatoid arthritis. Molecular stratification adds further granularity by identifying individuals with high-risk genetic variants (e.g., polymorphisms in VDR, ESR1, and OPG), epigenetic alterations (e.g., DNA methylation changes in bone-regulatory genes), and abnormal circulating biomarkers (e.g., elevated sclerostin, CTX, P1NP). Polygenic risk scores and genome-wide association studies (GWAS) are increasingly used to integrate multiple genetic signals, enhancing prediction models beyond traditional clinical factors.

Clinical Features

Fragility fractures may present with acute pain, deformity, and functional impairment, but vertebral fractures often remain clinically silent. Recurrent fractures are common and signal progressive skeletal fragility. Molecular stratification does not alter the classical clinical presentation but enables identification of high-risk individuals before fracture occurrence. For example, patients with high-risk genotypes or unfavorable biomarker profiles may warrant closer monitoring and early intervention despite normal BMD or absence of clinical risk factors.

Diagnosis

Diagnosis of fragility fractures traditionally relies on clinical assessment and imaging, with dual-energy X-ray absorptiometry (DXA) as the gold standard for BMD measurement. However, BMD alone fails to capture the full spectrum of fracture risk. Incorporation of molecular data such as genetic testing for specific SNPs, serum biomarker panels, and epigenetic profiling can enhance diagnostic precision. Emerging techniques, including next-generation sequencing and high-throughput proteomics, are poised to revolutionize risk assessment by providing individualized molecular signatures predictive of fragility fracture susceptibility.

Treatment & Management

Management of fragility fracture risk involves both pharmacologic and non-pharmacologic strategies. Bisphosphonates, denosumab, and selective estrogen receptor modulators remain mainstays of pharmacotherapy, while anabolic agents such as teriparatide and romosozumab offer additional benefit in selected high-risk patients. Molecular stratification may guide therapeutic decisions, such as identifying patients likely to respond favorably to specific agents based on genetic or biomarker profiles. Non-pharmacologic measures such as fall prevention, weight-bearing exercise, calcium and vitamin D supplementation, and management of secondary causes remain essential components of comprehensive care.

Recent Advances / Emerging Therapies

Recent years have witnessed the advent of novel molecularly-targeted therapies and diagnostic approaches. Monoclonal antibodies against sclerostin (e.g., romosozumab) and cathepsin K inhibitors represent significant advances, with efficacy demonstrated in high-risk populations. Liquid biopsy techniques for circulating microRNAs and cell-free DNA offer promise for early detection of skeletal fragility. Machine learning algorithms incorporating polygenic risk scores and multimodal biomarker data are being developed to refine risk prediction. Personalized medicine approaches, integrating molecular stratification, are expected to transform fracture prevention and management paradigms.

Guideline Recommendations

Current clinical guidelines from organizations such as the National Osteoporosis Foundation and International Osteoporosis Foundation emphasize individualized risk assessment and early intervention for high-risk patients. While molecular stratification is not yet universally incorporated into routine clinical guidelines, expert consensus supports its use in research settings and select clinical scenarios, particularly for patients with atypical fracture risk profiles. Ongoing studies are expected to inform future guideline updates, with a trend toward greater integration of molecular data into standard care algorithms.

Conclusion

Molecular stratification represents a paradigm shift in fragility fracture risk assessment, offering the potential for more precise identification of high-risk individuals and tailored intervention strategies. While substantial progress has been made, further research is needed to validate molecular markers, standardize testing protocols, and integrate these tools into routine practice. Ultimately, the incorporation of molecular profiling into clinical workflows is poised to enhance outcomes for patients at risk of fragility fractures, reduce the burden of disease, and advance the field of personalized bone health care.